newsfilter
← Latest News
GlobeNewswire·

Seer Announces Appointment of Anthony Bazarko as Chief Commercial Officer

  • Seer, Inc. (NASDAQ: SEER) appointed Anthony Bazarko as Chief Commercial Officer on May 04, 2026.
  • Bazarko brings over two decades of commercial leadership experience in life sciences, diagnostics, & biotechnology.
  • He previously served as President & CEO of Biologos from 2022 to 2025, leading its acquisition by Ampersand Capital Partners.
  • His prior role as CCO at Specific Diagnostics involved developing a global GTM strategy that resulted in an acquisition by bioMérieux.
  • Earlier career highlights include a VP role at Leica Biosystems (Danaher Corporation) & senior leadership positions at Roche Diagnostics Corporation.
  • At Seer, Bazarko will lead Sales, Marketing, & Customer Experience organizations to accelerate adoption of the Proteograph ® Product Suite.
  • CEO Omid Farokhzad stated Bazarko's appointment supports Seer's mission to advance AI-driven biology & global proteomics access.
  • Bazarko noted the convergence of technological capability & market demand for deep proteomic data acquisition.
  • Seer's products are for research use only & not intended for diagnostic procedures.
  • The press release includes standard forward-looking statements regarding Seer's plans & expectations.